Navigation Links
Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
Date:5/19/2009

ll six assessment periods, including Week 72, in CAPACITY 2, and at all four of the assessment periods through Week 48 in CAPACITY 1, but not at Week 72. An analysis of pooled data from the two CAPACITY studies showed that placebo-treated patients experienced a mean of 76 mL more decline in FVC than patients who received pirfenidone at Week 72. At Week 48, patients who received pirfenidone experienced a mean of 169 mL less FVC decline compared to placebo in CAPACITY 2 (p=0.002) and a mean of 54 mL less FVC decline in CAPACITY 1 (p=0.006). This pattern of change is consistent with that observed at Week 52 in the Phase 3 study of pirfenidone conducted by Shionogi.

Categorical Analysis of Change in Six-Minute Walk Test (6MWT) Distance

Post-hoc analyses of data from the 826-patient INSPIRE trial suggested that patients experiencing a 50-meter decrement in distance walked during the 6MWT at six months had an approximately 2.5-fold increased risk in mortality. Using this threshold, 33% and 47% of pirfenidone and placebo patients, respectively, in CAPACITY 1 (p=0.013), and 37% and 47% of pirfenidone and placebo patients, respectively, in CAPACITY 2 (p=0.032) experienced this magnitude of change. In a pooled analysis, 35% and 47% of pirfenidone and placebo patients, respectively, experienced a change that exceeded this threshold (p=0.001).

Safety and Tolerability Results

Safety data presented for both studies showed that pirfenidone given as 2403 mg per day was safe and generally well tolerated. In CAPACITY 2, 83% and 90% of surviving, lung transplant-free patients completed therapy per protocol in the pirfenidone and placebo groups, respectively, and 82% and 90%, respectively, of patients did so in CAPACITY 1. The percentage of patients discontinuing treatment due to an adverse event across both studies combined was 15% and 9% in the pirfenidone and placebo groups, respectively.

'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
4. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
5. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
6. AlphaVax Announces Promising Results in Melanoma Studies
7. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
8. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
9. Bionovo Announces First Quarter 2009 Highlights and Financial Results
10. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
11. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 Aileron Therapeutics, Inc. ... Global Markets Direct,s, ,Aileron Therapeutics, Inc. - ... of the Aileron Therapeutics, Inc.,s pharmaceutical research and ... on the current therapeutic developmental pipeline of Aileron ... stages, therapeutics assessment by drug target, mechanism of ...
(Date:9/30/2014)... , Sept. 30, 2014  Decision Resources Group finds that ... Australia , China , ... expand at a strong rate through 2023. Dental implant procedure volumes ... as patient awareness rises. Other key findings from Decision ... dental implant market: , Dental implant penetration: Penetration ...
(Date:9/30/2014)... 2014 According to ... by Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), Instruments ... Application (Immunology, Oncology) & by End User ... MarketsandMarkets, provides a detailed overview of the ... trends, and strategies impacting the global glycomics ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
... and Company) (NYSE: BDX ), a global medical technology company,announced today that ... Credit Suisse 2007 Healthcare Conference ... (ET), Lazard Capital ... November 27, 2007 - 9:00 a.m. (ET) A live webcast ...
... Golimumab Achieved Primary and Major Secondary Endpoints in ... Trial Completed to Date in Psoriatic Arthritis, ... arthritis,receiving monthly subcutaneous (SC) injections of golimumab (CNTO ... and skin,manifestations of the disease, according to findings ...
Cached Medicine Technology:Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 2Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 3Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 4Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 5Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 6Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 7Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 8
(Date:10/1/2014)... (PRWEB) October 01, 2014 ... networking and relationship-marketing firm, announced today the ... Executive® and Project of the Year Awards ... makers representing organizations in financial services, commercial, ... large-scale technology endeavors that address key issues ...
(Date:10/1/2014)... October 01, 2014 Beverly Hills licensed ... Mojas is celebrating 20 years of private practice in ... of people to achieve greater joy and fulfillment in ... of warning signs and suggestions for anyone who suspects ... explains: “Believe it or not, it’s not always ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 NoteSwift Inc., ... EHR versions 10.0, 12.1 and 13.0. NoteSwift is the ... as commands to navigate and document clinical information at ... provider spends creating a patient note by more than ... of the major pain points providers state impedes EHR ...
(Date:10/1/2014)... in Bahir Dar, Ethiopia, at the occasion of ... gathered some 150 African and international leishmaniasis experts, ... safety and efficacy monitoring plan, carried out ... Sudan, Uganda, and Ethiopia, were presented to key ... to treatment of kala-azar with the combination of ...
(Date:10/1/2014)... 01, 2014 Dr. Saj Jivraj, one ... prosthodontists, is traveling to Chennai, India, tomorrow to speak ... 2 and 3. , Dr. Jivraj is founder of ... Oxnard, Calif., and one of the world’s foremost prosthodontists, ... replacement. He is speaking to the Indian Society of ...
Breaking Medicine News(10 mins):Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 3Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 4Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 5
... directs the University of Southern California Center for ... to evaluate robots as exercise coaches for adults of ... The effort, entitled "Robot Motivator: Towards Adaptive Health ... of virtual social characters on people,s motivation to exercise. ...
... , , - ... 41% from 31% in Q3 2008 , - Q3 2009 Operating ... 2009 Pre-tax Income Increases 168% from same period in 2008 , ... LWAY ), makers of the nutritious, probiotic dairy beverage called kefir, ...
... of this group with better preventive care, , THURSDAY, Nov. ... health measures can prolong lives, but only 25 percent of ... getting these recommended screenings, a new report shows. , Prepared ... and the American Medical Association, the report also lays out ...
... no more likely to have post-operative complications than those ... uterine fibroids, according to a study at Henry Ford ... fibroids, leaving the uterus intact and preserving the ability ... obese patient can present difficulties for the most experienced ...
... ... in Buffalo, NY, launched their revitalized and interactive website Monday, November 16, 2009. The ... . The project was initiated to provide users with an enhanced shopping and ordering ... (PRWEB) November 18, ...
... MELVILLE, N.Y., Nov. 19 Long Island IVF, a full ... patients achieve successful pregnancies, is now offering a new program ... treatment. Through this program and a partnership with In Vitro ... amount of money couples pay for their comprehensive treatment plans ...
Cached Medicine News:Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 2Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 3Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 4Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 5Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 6Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 7Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 8Health News: Too Few Older Adults Get Recommended Screenings 2Health News: Too Few Older Adults Get Recommended Screenings 3Health News:Patient's weight not linked to success of fibroid surgery 2Health News:Great Customer Service Just Got Better as Emedco Announces the Launch of their Completely Updated and Enhanced Website 2Health News:Great Customer Service Just Got Better as Emedco Announces the Launch of their Completely Updated and Enhanced Website 3Health News:Long Island IVF to Offer IVF Financial Share Program, Limiting Costs and Providing Refunds if IVF is Not Successful 2
... The Crossover system of implants and ... range of posterior rod construct in the ... in this system are available in three ... cross connectors can be used with the ...
Multiwindow transcranial and peripheral Doppler system....
... Multi frequency and multigate ... detection and fitted with ... tests for hemodynamic evaluation. ... as well for routine ...
One channel transcranial Doppler...
Medicine Products: